• In August 2026, Lantheus Holdings received U.S. FDA approval for TAUKLARIFY (florquinitau F 18, MK-6240), a PET brain imaging agent to help assess tau neurofibrillary tangle pathology in adults with cognitive impairment being evaluated for Alzheimer’s disease, supported by data from more than 500 subjects across multiple clinical trials.
• This approval not only broadens Lantheus’s Alzheimer’s imaging portfolio but also reinforces its role as a key partner to pharmaceutical companies developing Alzheimer’s therapies through its Pharma Solutions business.
• We’ll now examine how TAUKLARIFY’s FDA approval, particularly its role in identifying tau pathology in Alzheimer’s evaluation, reshapes Lantheus’s investment narrative.

This technology could replace computers: discover 24 stocks that are working to make quantum computing a reality.

Lantheus Holdings Investment Narrative Recap

To own Lantheus, you need to believe that it can turn its radiopharmaceutical portfolio into a more diversified, durable earnings base rather than a PYLARIFY-dependent story. TAUKLARIFY’s FDA approval supports that diversification and strengthens the Alzheimer’s imaging pillar, but it does not remove the near term over-reliance on PYLARIFY or the pricing and reimbursement pressures that remain the key risk to margins and earnings visibility.

Among recent announcements, the pending Curium acquisition agreement stands out as most relevant, because it could ultimately determine how TAUKLARIFY is scaled commercially. While Lantheus continues to operate independently until the expected close in the first half of 2027, investors now have to factor in both deal execution risk and the question of how this Alzheimer’s asset fits into Curium’s broader radiopharmaceutical platform and capital allocation priorities.

However, even with TAUKLARIFY’s approval, investors should be aware that pricing pressure in core products could still...

Lantheus Holdings’ narrative projects $1.9 billion revenue and $395.4 million earnings by 2029.

Uncover how Lantheus Holdings' forecasts yield a $107.22 fair value, a 6% upside to its current price.

Exploring Other Perspectives

While consensus focuses on diversification and PYLARIFY risk, the most optimistic analysts see Alzheimer’s diagnostics like TAUKLARIFY as central to a potential US$2.2 billion revenue and US$751.3 million earnings story, highlighting how far views can differ and why you may want to compare several scenarios before deciding what this new approval really means for Lantheus.

Explore 4 other fair value estimates on Lantheus Holdings - why the stock might be worth over 2x more than the current price!

Form Your Own Verdict

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Lantheus Holdings research is our analysis highlighting 4 key rewards that could impact your investment decision.
• Our free Lantheus Holdings research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Lantheus Holdings' overall financial health at a glance.

Interested In Other Possibilities?

Don't miss your shot at the next 10-bagger. Our latest stock picks just dropped:

• The future of work is here. Discover the 37 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
• We've uncovered the 12 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
• Invest in the nuclear renaissance through our list of 92 elite nuclear energy infrastructure plays powering the global AI revolution.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.